The fourth line of treatment for patients with resistant hypertension should include mineralocorticoid receptor antagonists such as spironolactone, as demonstrated in the PATHWAY-2 trial and ...

Two authors independently screened and extracted key data using a structured form. We identified 13 published studies on diuretics in HFpEF, with 1 evaluating thiazide use, 7 on mineralocorticoid ...

CHICAGO -- A mineralocorticoid receptor antagonist (MRA ... perhaps finerenone (Kerendia), may offer a better chance of MRAs showing an effect in the MI setting. The FDA has approved finerenone ...

2 Once primary aldosteronism is treated with mineralocorticoid receptor antagonists instead of, or in addition to, standard antihypertensive medications, the associated cardiovascular risk can ...

Figure. The mineralocorticoid receptor (MR) action in preadipocytes and adipocytes. Cytosolic MR is activated by both aldosterone and cortisol. The source of aldosterone is both from the circulation ...